We protect your health through science
Investigation
Hepatitis C and other RNA virus
Research Lines
Content with Investigacion .
Líneas de investigación prioritarias
1. Estudio de los procesos de latencia y reactivación del VIH-1: principales mecanismos homeostáticos responsables de la latencia proviral y la generación de los reservorios virales que imposibilitan la erradicación de la enfermedad.
2. Estudio de dianas terapéuticas para impedir la replicación viral activa durante la infección aguda o primaria y para interferir con la renovación del reservorio viral: análisis de fármacos inhibidores de las kinasas de linfocitos PKC o kinasas de la familia Src como p56Lck.
3. Análisis de los mecanismos de transactivación responsables de la replicación viral activa en linfocitos T CD4+: mecanismos virales implicados en reactivación del provirus.
4. Estudio de mecanismos que impidan la infección y replicación viral eficaz en células del reservorio viral secundario como son los monocitos/macrófagos.
5. Análisis de la resistencia a la infección por VIH-1 en linfocitos T CD4+ aislados de pacientes con distrofia muscular de cintura escapulohumeral/pélvica 1F (LGMD1F), que portan un defecto en el gen de la transportina-3 (tnpo3).
6. Estudio de la sinergia NF-B/Tat para la identificación de nuevas dianas terapéuticas.
7. Estudio de cambios de expresión en el transcriptoma y modificaciones postraduccionales en el proteoma de linfocitos T CD4+ que expresan Tat intracelular y su impacto sobre la estructura del citoesqueleto celular: mecanismo potencial de supervivencia de los reservorios virales.
8. Análisis de los mecanismos de degradación de p65/RelA (NF-B) y su importancia en la infección por VIH-1.
9. Estudio de las modificaciones en el metabolismo del RNA inducidas por la expresión intracelular de Tat y su papel en los mecanismos de supervivencia celular y aumento de la replicación viral.
Otras líneas de investigación
1. Estudio de la respuesta humoral y celular desarrollada en pacientes con Long COVID o COVID persistente.
2. Análisis de biomarcadores predictivos de gravedad en pacientes con distintas presentaciones de COVID-19.
3. Estudio de la respuesta inmune frente a la infección natural por SARS-CoV-2 o por la vacunación frente al COVID-19 desarrollada por pacientes con enfermedades oncohematológicas en estado de inmunodeficiencia.
4. Definición de biomarcadores predictivos de recaída en pacientes con leucemia mieloide crónica que hayan interrumpido el tratamiento con inhibidores de tirosina kinasas.
Research projects
Content with Investigacion .
Projects with public funding
TITLE: Virulence factors of pathogenic yeasts and their influence on the host.
FUNDING ENTITY: Ministry of Education and Science.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 15,000 EUROS
TITLE: Characterization of fungal giant cells and their role during infection in mammals.
FINANCING ENTITY: Instituto de Salud Carlos III
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2006-2007
AMOUNT: 55,000 EUROS
TITLE: Search and identification of genes involved in the resistance to antifungal agents in
Cryptococcus neoformans
FUNDING ENTITY: Ministry of Science and Innovation.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/FINISH: 2008-2010
AMOUNT: 25,000 EUROS
COLLABORATORS: Juan Luis Rodríguez Tudela (National Center of Microbiology, ISCIII. Madrid); Manuel Cuenca Estrella (National Center of Microbiology, ISCIII. Madrid); Maria Jose Gianinni (Faculdade de Ciências Farmacêuticas-UNESP). Brazil
TITLE: Role of morphological changes of the pathogenic yeast Cryptococcus neoformans during host infection.
FUNDING ENTITY: Ministry of Science and Innovation. National Plan Program “Non-oriented Fundamental Research”, area of Biomedicine, SAF2008-03761.
POSITION HELD: Principal Investigator, Contracted “Ramón y Cajal”.
START/END: 2009-2011
AMOUNT: 46,000 EUROS
PROJECT TITLE: Identification of the molecular mechanisms involved in the morphogenesis of Cryptococcus neoformans and study of their function during infection.
FUNDING ENTITY: Ministry of Science and Innovation, National Plan for Non-Oriented Fundamental Research, Biomedicine Area, Referencia: SAF2011-25140
DURATION FROM: January 2012 UNTIL: December 2014
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
This project has an FPI grantee granted.
SUBSIDY: 90.000 euros
TITLE: Importance of morphogenesis in the virulence of pathogenic yeast Cryptococcus neoformans and improvement of amphotericin B-based cryptococcosis therapy. Reference: SAF2014-25140
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/FINISH: 2015-2017
Funding: 100.000 €.
TITLE: Study of the molecular basis and factors inducing morphological changes in Cryptococcus neoformans and characterization of new therapeutic strategies. Reference: SAF2017-86912-R
FUNDING ENTITY: MINECO (Call for R+D+I Projects “RETOS INVESTIGACION)
POSITION HELD: Principal Investigator
START/END: 2018-2020
Funding: 106.000 €.
TITLE: Mechanisms of adaptation of the pathogenic yeast Cryptococcus neoformans to the lung. Reference: PID2020-114546RB
FUNDING ENTITY: Ministry of Science and Innovation, State Research Agency (Call “Proyectos I+D+I” 2020 - Modalities “Research Challenges” and “Knowledge Generation”).
POSITION HELD: Principal Researcher
START/END: 01/09/2021-31/05/2025
Funding: 143,990 €.
TITLE: Precision medicine against antimicrobial resistance. MePRAM Project.
FUNDING ENTITY: Research Projects on Precision Personalized Medicine of the Strategic Action in Health 2021-2023, under the PERTE for Vanguard Health and charged to the European funds of the Recovery, Transformation and Resilience Plan.
POSITION: Collaborator (Principal Investigator: Jesús Oteo Iglesias)
START/FINISH: 2023-2025
Funding: 4.339.500 €.
TITLE: Centre for Biomedical Research in Network. Infectious Diseases Area (CIBERINFEC)
Funding Agency: Insituto de Salud Carlos III. Reference: CB21/13/00105
Dates: 2022-2026 Funding: 85.000 € (first year)
PI: Emilia Mellado Terrado / CoPI: Óscar Zaragoza Hernández
TITLE: Study of the genetic, metabolic and cellular determinants that influence titan cell formation in the fungal pathogen Cryptococcus neoformans and correlation with antifungal exposure.
CALL FOR PROJECTS: Knowledge Generation Projects.
FUNDING ENTITY. State Research Agency. Ministry of Science, Innovation and Universities.
REFERENCE: Project PID2023-148686OB-I00 Project funded by MICIU/AEI/10.13039/501100011033 and by FEDER, EU.
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
START/END: 2024-2027
FUNDING: 180.000 €.
TITLE: Characterization of azole-resistant Candida parapsilosis isolates associated with hospital outbreaks: New strategies for their detection and treatment.
CALL: Strategic Action in Intramural Health.
FUNDING ENTITY. Carlos III Health Institute.
REFERENCE: AESI-2024 PI24CIII/00051
PRINCIPAL RESEARCHER: Oscar Zaragoza Hernández / Laura Alcázar Fuoli
START/FINISH: /01/012025-31/12/2027
FUNDING: 70.000 €.
Projects financed by biotechnology companies
PROJECT TITLE: Amphores. Evaluation of the induction of oxidative damage by Amphoterin B in susceptible and resistant yeast species.
FUNDING ENTITY: Gilead
DURATION FROM: 2011 TO: 2012
PRINCIPAL INVESTIGATOR: Oscar Zaragoza Hernández
GRANT: 55,000 euros
TITLE: Fungomics. Evaluation of the activity of amphotericin B and other antifungals against human pathogenic fungi.
FINANCING ENTITY: Gilead
POSITION HELD: Principal Investigator
START/END: 2019-2020
TITLE: Antifungal susceptibility testing of a set of Candida spp to CD101 and anidulafungin in five microdilution plates.
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2018
TITLE: Cidara MultiCentre EUCAST study
FUNDING ENTITY: Cidara
POSITION HELD: Principal Investigator
START/END: 2016
TITLE: Characterization of triazole-resistant Candida parapsilosis isolates from Spanish hospitals
FUNDING ENTITY: Gilead Science
POSITION HELD: Principal Investigator
START/END: 2022-2023
TITLE: EUCAST multicentre MIC testing of manogepix meeting EUCAST ECOFF setting criteria
FUNDING ENTITY: Pfizer
POSITION HELD: Principal Investigator
START/END: 2023
Publications
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.
10.1186/s40249-021-00894-5. 9. Brochado O, Martínez I (*), Berenguer J, Medrano L, González-García J, Jiménez-Sousa MA, Carrero A, Hontañón V, Navarro J, Guardiola JM, Pérez-Latorre L, Micán R, Fernández-Rodríguez A (‡), Resino S (* ‡). HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. J Biomed Sci 2021; 28:23 (A; FI= 12.77; D1, Medicine, Research & Experimental; JCR 2021). PMID: 33785040. DOI: 10.1186/s12929-021-00718-6.
PUBMEDRelationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis.
12. García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa Ma, Fernández-Rodríguez A, Guzmán-Fulgencio M; Resino S (*). Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis. Hepatology. 2014, 6(5):1541-1550. (A; FI= 11.05; D1, Gastroenterology & Hepatology; JCR 2014). PMID: 24975775. DOI: 10.1002/hep.27281.
PUBMEDFTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
13. Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Álvarez M, Aldamiz-Echevarría T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S (*). FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014, 12:198. (A; FI= 7.34; D1, Medicine, General & Internal; JCR 2014). PMID: 25367448. DOI: 10.1186/s12916-014-0198-y.
PUBMEDHLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
14. Guzmán-Fulgencio M, Berenguer J; Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosin J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S (*). HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013; 27(8):1231-1238. (A; FI= 6.55; D1, Infectious Diseases; JCR 2013). PMID: 23811951. DOI: 10.1097/QAD.0b013e32835f5b9c.
PUBMEDEva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval.
Eva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval. Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects. J Infect. 2022 Jul 10;S0163-4453(22)00415-7. doi: 10.1016/j.jinf.2022.07.005.
DOIEuropean mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy.
15. Guzmán-Fulgencio M; Berenguer J, Micheloud D, Fernández-Rodríguez A; García–Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosin J, Aldámiz-Echevarría T, Catalán P, López JC, Resino S (*). European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemoth 2013; 68 (10): 2349–2357 (A; FI= 5.44; D1, Infectious Diseases; JCR 2013). PMID: 23749950. DOI: 10.1093/jac/dkt206.
PUBMEDMaría Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain.
María Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain. Emerg Infect Dis. 2022 Feb;28(2):394-402. doi: 10.3201/eid2802.211308.
DOINegredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013
Negredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013. Emerg Infect Dis. 2021 Jun;27(6):1754-1756. doi: 10.3201/eid2706.204643.
DOINegredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018.
Negredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018. Emerg Infect Dis. 2021 Apr;27(4):1211-1215. doi: 10.3201/eid2704.203462.
DOILaura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses
Laura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses. Davó et al. Parasit Vectors. 2020 May 29;13(1):270. doi: 10.1186/s13071-020-04110-5.
DOIMaría Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain
María Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain: Neurological and Gastrointestinal Complications. Viruses 2020 Jan 29;12(2):156. doi: 10.3390/v12020156.
DOINegredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015
Negredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015. Emerg Infect Dis. 2019 Jun;25(6):1177-1184. doi: 10.3201/eid2506.180877.
DOIRamírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain
Ramírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain. Viruses. 2019 Apr 19;11(4):360. doi: 10.3390/v11040360.
DOIMeta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals.
3. Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez‑Sousa MA, Fernández-Rodríguez A, Martínez I (‡), Resino S (*‡). Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2022; 56 (8): 1224-1234 (A; FI= 9.52; D1, Pharmacology & Pharmacy; JCR 2021).
PUBMED DOIAntibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later.
4. Martin-Vicente M, Carrasco I, Muñoz-Gomez MJ, Lobo AH, Mas V, Vigil-Vázquez S, Vázquez M, Manzanares A, Cano O, Alonso R, Sepúlveda-Crespo D, Tarancón-Díez L, Muñoz-Fernández MÁ, Muñoz-Chapuli M, Resino S#*, Navarro ML#, Martinez I#*. Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later. Birth. 2022 Jul 8:10.1111/birt.12667. doi: 10.1111/birt.12667. Online ahead of print. PMID: 35802776.
PUBMEDHepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
5. Pérez-García F, Vázquez-Morón S, Burgueño-García I, José Muñoz-Gómez M, Zea-Sevilla MA, Calero M, Martínez I#, Rábano A#, Resino S#. Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study. J Infect Dis. 2022 Jun 27:jiac268. doi: 10.1093/infdis/jiac268. Online ahead of print. PMID: 35759220 (A; FI= 7.759; Q1 Microbiology; JCR 2021).
PUBMEDNegative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis.
6. Sepúlveda-Crespo D, Yélamos MB, Díez C, Gómez J, Hontañón V, Torresano-Felipe F, Berenguer J, González-García J, Ibañez-Samaniego L, Llop E, Olveira A, Martínez J, Resino S (‡ *), Martínez I (‡ *). Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomed Pharmacother 2022, 150: 113024. (A; FI= 7.42; D1, Pharmacology & Pharmacy; JCR 2021).
PUBMED DOI. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study.
7. Álvaro-Meca A, Goez MDC, Resino R, Matías V, Sepúlveda-Crespo D, Martínez I#, Resino S#. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study. Environ Res. 2022 Sep; 212(Pt B):113319. doi: 10.1016/j.envres.2022.113319. PMID: 35447151. (A; FI= 8.431; D1 Public, Environmental & Occupational Health; JCR 2021).
PUBMEDMisdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021.
8. Ryan P, Pérez-García F, Torres-Macho J, Bibiano C, Ignacio Lazo J, Castaño-Ochoa G, Vidal-Alcántara EJ, Muñoz-Gómez MJ, Martínez I#, Resino S#. Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021. J Infect. 2022 May; 84(5):e42-e44. doi: 10.1016/j.jinf.2022.03.013. PMID: 35306106 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).
PUBMEDSimilar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19.
11. Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, Díez C, Micán R, Pérez-Elías MJ, García-Fraile LJ, Peraire J, Suárez-García I, Jiménez-Sousa MÁ, Fernández-Rodríguez A, Vázquez M, Ryan P, González-García J, Jarrín I, Mas V, Martínez I#, Resino S#. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.002. PMID: 34752819 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).
PUBMEDContent with Investigacion .
-
Óscar Zaragoza Hernández
Research Professor
ORCID code: 0000-0002-1581-0845
Dr. Oscar Zaragoza graduated in Biology from the Complutense University of Madrid in 1995 and obtained his PhD from the Autonomous University of Madrid. He completed his doctoral thesis (2000) at the CSIC under the direction of Dr. Juana María Gancedo on the topic of glucose catabolite repression in Saccharomyces cerevisiae. During this period, he was also tutored by Dr. Carlos Gancedo in collaborative projects, that allowed him to start working with the pathogenic yeast Candida albicans.
After a brief postdoctoral stay in the same laboratory, in 2001, he joined the laboratory of Dr. Arturo Casadevall (Albert Einstein College of Medicine, New York), where he specialized in research into virulence mechanisms of pathogenic fungi, mainly Cryptococcus neoformans. In 2006 he joined the National Center for Microbiology of the ISCIII thanks to a “Ramón y Cajal” contract and he became staff scientist in 2009. Currently, he occupies the rank of Research Professor of the OPIs.
During his career, he has published more than 140 articles, 4 book chapters and a popular book ("Microscopic fungi: Friends or Enemies?"). He has obtained public and private projects, and participates as CoIP of a CIBERINFEC group. He has supervised seven doctoral theses, and numerous master's thesis projects.
-
Alba Torres Cano
PhD student (FPI contract)
ORCID code: 0009-0008-3151-1803
Alba Torres Cano has a degree in Health Biology from the University of Alcalá de Henares (UAH), and completed the master's degree "Microbiology Applied to Public Health and Infectious Diseases" from the UAH. He completed his master's thesis at the CNM under the direction of Dr. Zaragoza in 2022, focusing on pathogenic yeasts. In that year, he joined the ISCIII with an FPI predoctoral contract under the direction of Dr. Óscar Zaragoza.
-
-
Alejandra Lora Plaza
PhD student (FPI contract)
ORCID code: 0009-0004-4344-1583
Alejandra Lora Plaza graduated in Health Biology and completed the Master in Applied Microbiology in Public Health and Infectious Diseases Research (2021) at the University of Alcalá in both cases. She joined the Department of Microbiology of the Faculty of Biology of the University of Barcelona to carry out her internship and her final degree work. Subsequently, she did her Master's thesis at the Microbiology Laboratory of the Hospital Universitario Príncipe de Asturias. In 2022 she joined the Public Health and Epidemiology group at the Marqués de Valdecilla Research Institute (IDIVAL), Santander, as a research support technician. In 2024 he joined Dr. Concha Gil's group in the Department of Microbiology and Parasitology at the Faculty of Pharmacy of the Complutense University of Madrid focusing on yeasts.
In 2025 she joined ISCIII with a predoctoral FPI fellowship under the direction of Dr. Óscar Zaragoza.
List of staff